Target Name: PCOLCE
NCBI ID: G5118
Review Report on PCOLCE Target / Biomarker Content of Review Report on PCOLCE Target / Biomarker
PCOLCE
Other Name(s): PCOC1_HUMAN | procollagen C-proteinase enhancer 1 | Procollagen COOH-terminal proteinase enhancer 1 | procollagen C-endopeptidase enhancer | PCPE-1 | procollagen, type 1, COOH-terminal proteinase enhancer | PCPE | procollagen COOH-terminal proteinase enhancer 1 | Procollagen C-endopeptidase enhancer | Type I procollagen COOH-terminal proteinase enhancer | OTTHUMP00000210409 | Procollagen, type 1, COOH-terminal proteinase enhancer | type I procollagen COOH-terminal proteinase enhancer | Procollagen C-proteinase enhancer 1 | Type 1 procollagen C-proteinase enhancer protein | PCPE1 | type 1 procollagen C-proteinase enhancer protein | Procollagen C-endopeptidase enhancer 1

PCOLCE: Peroxisome Proliferator-Activated Receptor C Subfamily-Expressed Protein

PCOLCE (Peroxisome proliferator-activated receptor C subfamily-expressed) is a protein that is expressed in various tissues and organs in the human body. It is a member of the Peroxisome proliferator-activated receptor (PPAR) family, which is a subset of the tyrosine kinase receptor family. PPARs are involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

PCOLCE is a 14 kDa protein that is expressed in various tissues and organs, including liver, lung, heart, kidney, and pancreas. It is highly expressed in the liver, with lower levels found in the lung, heart, and kidney. PCOLCE is also expressed in various cell types, including macrophages, dendritic cells, and cancer cells.

One of the key functions of PCOLCE is its role in cell signaling. It is a potent negative regulator of the PPAR signaling pathway, which is a well-established regulator of various cellular processes, including inflammation, cell growth, and differentiation. The PPAR signaling pathway is a critical pathway that is involved in the regulation of cellular processes that are essential for human health and disease.

In addition to its role in cell signaling, PCOLCE is also a potential drug target. Its high expression in various tissues and organs makes it an attractive target for small molecule inhibitors. Furthermore, its role in cell signaling makes it a potential biomarker for various diseases , including cancer.

PCOLCE has been shown to be involved in the regulation of cellular processes that are important for cancer progression. For example, studies have shown that PCOLCE is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to support tumor growth. In addition, PCOLCE has been shown to be involved in the regulation of cell cycle progression, which is the process by which cells grow and divide.

PCOLCE has also been shown to be involved in the regulation of inflammation. Its high expression in various tissues and organs makes it an attractive target for anti-inflammatory agents. In addition, studies have shown that PCOLCE is involved in the regulation of immune cell function , which is important for the immune response to cancer.

In conclusion, PCOLCE is a protein that is expressed in various tissues and organs in the human body. It is a member of the Peroxisome proliferator-activated receptor (PPAR) family and is involved in various cellular processes, including cell signaling and cell cycle progression . Its high expression in various tissues and organs makes it an attractive target for small molecule inhibitors and potential drug targets. Further research is needed to fully understand the role of PCOLCE in cellular processes and its potential as a drug target or biomarker.

Protein Name: Procollagen C-endopeptidase Enhancer

Functions: Binds to the C-terminal propeptide of type I procollagen and enhances procollagen C-proteinase activity

The "PCOLCE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCOLCE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

PCOLCE-AS1 | PCOLCE2 | PCOTH | PCP2 | PCP4 | PCP4L1 | PCSK1 | PCSK1N | PCSK2 | PCSK4 | PCSK5 | PCSK6 | PCSK6-AS1 | PCSK7 | PCSK9 | PCTP | PCYOX1 | PCYOX1L | PCYT1A | PCYT1B | PCYT2 | PDAP1 | PDC | PDCD1 | PDCD10 | PDCD11 | PDCD1LG2 | PDCD2 | PDCD2L | PDCD4 | PDCD4-AS1 | PDCD5 | PDCD6 | PDCD6IP | PDCD6IPP2 | PDCD6P1 | PDCD7 | PDCL | PDCL2 | PDCL3 | PDCL3P4 | PDCL3P6 | PDE10A | PDE11A | PDE11A-AS1 | PDE12 | PDE1A | PDE1B | PDE1C | PDE2A | PDE2A-AS1 | PDE3A | PDE3B | PDE4A | PDE4B | PDE4C | PDE4D | PDE4DIP | PDE5A | PDE6A | PDE6B | PDE6C | PDE6D | PDE6G | PDE6H | PDE7A | PDE7B | PDE7B-AS1 | PDE8A | PDE8B | PDE9A | PDE9A-AS1 | PDF | PDGFA | PDGFA-DT | PDGFB | PDGFC | PDGFD | PDGFRA | PDGFRB | PDGFRL | PDHA1 | PDHA2 | PDHB | PDHX | PDIA2 | PDIA3 | PDIA3P1 | PDIA4 | PDIA5 | PDIA6 | PDIK1L | PDILT | PDK1 | PDK2 | PDK3 | PDK4 | PDLIM1 | PDLIM1P4 | PDLIM2